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ABSTRACT
Despite a growing number of splicing mutations
found in hereditary diseases, utilization of aberrant
splice sites and their effects on gene expression
remain challenging to predict. We compiled
sequences of 346 aberrant 50splice sites (50ss) that
were activated by mutations in 166 human disease
genes. Mutations within the 50ss consensus
accounted for 254 cryptic 50ss and mutations else-
where activated 92 de novo 50ss. Point mutations
leading to cryptic 50ss activation were most
common in the first intron nucleotide, followed by
the fifth nucleotide. Substitutions at position +5
were exclusively G4A transitions, which was largely
attributable to high mutability rates of C/G4T/A.
However, the frequency of point mutations at
position +5 was significantly higher than that
observed in the Human Gene Mutation Database,
suggesting that alterations of this position are
particularly prone to aberrant splicing, possibly
due to a requirement for sequential interactions
with U1 and U6 snRNAs. Cryptic 50ss were best
predicted by computational algorithms that accom-
modate nucleotide dependencies and not by
weight-matrix models. Discrimination of intronic
50ss from their authentic counterparts was less
effective than for exonic sites, as the former were
intrinsically stronger than the latter. Computational
prediction of exonic de novo 50ss was poor,
suggesting that their activation critically depends
on exonic splicing enhancers or silencers. The
authentic counterparts of aberrant 50ss were
significantly weaker than the average human 50ss.
The development of an online database of aberrant
50ss will be useful for studying basic mechanisms of
splice-site selection, identifying splicing mutations
and optimizing splice-site prediction algorithms.
INTRODUCTION
Mutations that inﬂuence pre-mRNA splicing represent
a substantial proportion of gene alterations leading to
Mendelian disorders (1). cDNA-based mutation studies of
disease genes that have a large number of introns showed
that splicing mutations accounted for about half of
mutated alleles (2,3). In contrast, estimates derived from
DNA-based mutation screening designed to scan coding
regions and ﬂanking intronic sequences have generally
been lower (1,4). As a signiﬁcant fraction of mutated
alleles in both recessive and dominant conditions has not
been identiﬁed, and the availability of RNA samples from
aﬀected individuals and their families is often problematic,
the overall contribution of intronic alterations acting at
the level of pre-mRNA splicing could be substantial.
In addition to single-gene disorders, DNA variants that
inﬂuence splicing may modify the risk of developing
complex diseases and their phenotypic manifestations, but
the overall role of this variability in the pathogenesis of
such conditions is only beginning to be explored (5–8).
The most common consequence of splicing mutations is
skipping of one or more exons, followed by the activation
of aberrant 50 (donor) splice sites (50ss), 30 (acceptor) splice
sites (30ss) and full intron retention (1,9,10). Mutation-
induced aberrant splice sites found in disease genes
often involve disruption of the consensus sequence
of the authentic sites, while activating a cryptic splice
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generated by mutations that create splice-site consensus
sequences. As described earlier (11), we refer to these
aberrant splice sites as cryptic and de novo, respectively,
even though the distinction between cryptic and de novo
sites may occasionally be vague, because disruption of the
authentic site can also create a new splice site consensus.
Cryptic 30ss are preferentially located in exons whereas
de novo 30ss usually reside in introns, which has been
attributed to splicing signal sequences upstream of the 30ss
that are required for selection of acceptor sites, including
the polypyrimidine tract (PPT) and the branch point
sequence (BPS) (12). In contrast to cryptic 30ss, cryptic 50ss
have a similar frequency distribution in exons and introns
and their number decreases with increasing distance
from the authentic 50ss (11). The human 50ss consensus
sequence is MAG|GURAGU (M is A or C; R is purine),
spanning from position  3 to position +6 relative to the
exon–intron junction. This sequence is critical but often
insuﬃcient for accurate 50ss recognition, and may require
auxiliary sequences in both introns and exons. These
sequences can repress or activate splicing and are referred
to as splicing silencers or enhancers, respectively (13–17).
The complementarity of the 50ss consensus to the 50 end of
U1 small nuclear RNA (snRNA) exerts a dominant eﬀect
on 50ss selection, but auxiliary sequences may exhibit
a more prominent role in selection of competing 50ss with
lower base-pairing complementarity (18,19). In addition,
the intrinsic structural properties of the RNA molecule
may hinder 50ss availability for basal splicing factors,
thus controlling splicing eﬃciency (20–22). Moreover,
50ss selection can also be inﬂuenced by the presence
of sequence motifs speciﬁc for RNA-binding proteins
(23) and by the rate at which the pre-mRNA is
transcribed (21).
A variety of methods have been used to computation-
ally predict the 50ss strength and recognition, including
nucleotide frequency matrices (24,25), machine-learning
approaches and neural networks (NNs) (26,27) and
methods employing putative base-pairing interactions of
50ss with U1 snRNP (28–30) and interdependence between
adjacent or more distant positions of the splicing
consensus sequences (31). Exon-prediction algorithms
that take into account protein-coding information may
perform better than those that rely only on signals present
in the splice sites (32). However, it is unknown which
models best predict the localization of cryptic or de novo
50ss that were activated in vivo.
In the present study, we compiled nucleotide sequences
of cryptic and de novo 50ss that have been reported
previously in human disease genes since the ﬁrst descrip-
tion of disease-causing aberrant splice sites (33–35).
This resource is being made available to the public
through an online retrieval and submission tool termed
DBASS5 (database of aberrant 50 splice sites). In addition,
we provide a detailed characterization of the underlying
mutation pattern, a comparison of the nucleotide compo-
sition of aberrant and corresponding authentic 50ss, and
we evaluate the performance of computational tools that
predict their utilization.
MATERIAL AND METHODS
Compilation of mutation-induced aberrant 50ss inhuman
diseasegenes
Aberrant 50ss were identiﬁed by searching home pages of
peer-reviewed journals and PubMed (http://www.ncbi.
nlm.nih.gov/entrez/query.fcgi). They were included in
the database and selected for further analysis if (i) they
resulted from disease-causing or -predisposing mutations
or variants in human genes; (ii) aberrant RNA products
spliced to new 50ss were veriﬁed by nucleotide sequencing;
and (iii) their sequences or reliable identiﬁers were
published in peer-reviewed journals between 1981 and
January 2007. We also included 22 cases of aberrant 50ss
that were conﬁrmed by minigene assays with wild-type
and mutated reporter constructs transfected into mamma-
lian cells, but from which patients’ RNA samples were not
available. These criteria were similar to those used for
a recently published analysis of aberrant 30ss (36).
Aberrant 50ss were manually validated by mapping the
information in the literature to sequences in the Human
Genome Project databases. Nucleotide sequences of
authentic, mutated and aberrant 50 and 30ss are avail-
able online in the Database of Aberrant Splice Sites
http://www.dbass.org.uk/, which consists of the recently
described DBASS3 (36) and the newly developed
DBASS5.
Computational methodsto predictaberrant 50ss
Validated sequences of aberrant and corresponding
authentic 50ss were used as input ﬁles for seven publicly
available splice-site prediction algorithms. The Shapiro
and Senapathy (S&S) matrix is based on nucleotide
frequencies of 50ss and assumes independence between
individual positions of the 9-nt consensus (24,25).
The S&S matrix scores were computed using an
online tool available at http://ast.bioinfo.tau.ac.il/
SpliceSiteFrame.htm. To take into account known depen-
dencies between adjacent and non-adjacent positions of
the 50ss consensus, the compiled sequences were analysed
using the ﬁrst-order Markov model (MM) and the
maximum entropy (ME) model (31). The former method
considers dependencies between adjacent positions,
whereas the latter model approximates short-sequence
motif distributions with the ME distribution and may
include dependencies between non-adjacent as well as
adjacent positions. The maximum dependence decomposi-
tion model (MDD) is a decision-tree approach that
accentuates the strongest dependencies in the early
branches of the tree (37). The MM, ME, MDD and
weight-matrix (WMM) scores, which extract single
nucleotide probabilities for each position from a training
set (38), were computed using online tools at http://
genes.mit.edu/burgelab/maxent/
Xmaxentscan_scoreseq_acc.html. The HBond algorithm,
which analyses individual hydrogen-bonding patterns to
the U1 snRNA 50 end irrespective of nucleotide frequen-
cies and assumes that the threshold values for U1 snRNP
binding are inﬂuenced by speciﬁc SR proteins (29)
was computed using a web application available at
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The NN algorithm is a machine-learning approach that
recognizes sequence patterns once it is trained with DNA
sequences encompassing authentic splice sites (27). We
used the NN splice site predictor NNSPLICE (v. 0.9) at
http://www.fruitﬂy.org/seq_tools/splice.html. The free
energy (G) of predicted 50ss/U1 base-pairing was
computed using OligoArrayAux (39), which is available
at http://www.bioinfo.rpi.edu/applications/hybrid/Oligo-
ArrayAux.php. Finally, the number of H bonds (#H)
between 50ss and U1 was computed using a web tool at
http://ast.bioinfo.tau.ac.il/SpliceSiteFrame.htm.
To compare the strength of aberrant or authentic 50ss
with a large number of human 50ss, we used the sequences
of 8415 50ss reported previously (31). The non-parametric
Wilcoxon–Mann–Whitney rank test (Stat-200, v. 2.01,
Biosoft Ltd., UK) was employed to test the signiﬁcance of
score diﬀerences between authentic and aberrant 50ss in
each category.
DBASS5 construction
DBASS5 (database of aberrant 50 splice sites) is an online
retrieval and submission tool for mutation-induced
aberrant 50ss available at http://www.dbass.org.uk/5/,
complementing a recently described sister database of
aberrant 30ss, termed DBASS3 (36). The web application
was created using the Microsoft ASP and ASP.Net server
technology (http://www.asp.net), and Microsoft SQL
Server database software (http://www.microsoft.com/sql/).
In addition to aberrant 50ss induced by disease-associated
germline and somatic mutations, DBASS5 contains
naturally occurring DNA variants that were shown to
modify both the relative expression of RNA products
spliced to alternative 50ss and the disease predisposition.
Polymorphisms that control exon skipping levels or
full intron retention events have not been included
in DBASS5.
RESULTS
Mutations that activate aberrant 50ss
An exhaustive search for previously published aberrant
50ss identiﬁed 305 unique aberrant 50ss in 166 genes
(Table 1). They were generated by a total of 26 deletions/
duplications, 3 insertions, 2 complex alterations and 315
point mutations (Table 2). These alterations were
described in a total of 264 publications.
The number of reported cryptic 50ss was almost three
times higher than the number of de novo 50ss (Table 1).
Cryptic 50ss were usually activated by single-nucleotide
substitutions of guanosine (G) residues, which were
 3-times more common than mutations of the remaining
nucleotides (177 versus 57, P510
 15, Table 2).
Conversely, substituting adenosines accounted for
almost every other point mutation. Among single-
nucleotide substitutions leading to de novo 50ss, cytosine
was the most frequently mutated nucleotide (32/81, 40%).
In contrast, no de novo 50ss have thus far been reported
to be created by a point mutation introducing
cytosine (Table 2).
The overall distribution of unique point mutations
within the 9-nt consensus sequence was highly non-
random both for cryptic and de novo 50ss (Figure 1).
For cryptic 50ss, point mutations were most common at
the highly conserved position +1 relative to the natural
intron/exon junctions (39.4%). Interestingly, the second
most frequently mutated position was the ﬁfth intron
nucleotide (21.6%), followed by positions +2 (14.7%)
and –1 (14.3%). Point mutations at positions +3, +4, +6
and  2 each accounted for 53% of all the single-
nucleotide substitutions. In contrast to cryptic 50ss,
the most frequent point mutations resulting in de novo
50ss were at the highly conserved ﬁrst (28%) and second
(34%) intron nucleotides (Figure 1). Single-nucleotide
substitutions at position +5 were found only in 5/81
(6%) unique de novo 50ss as opposed to 50/234 unique
cryptic 50ss (
2=8.6, P=0.003). The ratio of point
Table 1. Summary of aberrant 50 splice sites
Location of cryptic or de novo 50 splice sites Exon Intron Both
Mutation In the 9-nt 50ss
consensus (cryptic)
Elsewhere
(‘de novo’)
In the 9-nt 50ss
consensus (cryptic)
Elsewhere
(‘de novo’)
All mutations
Number of genes 80 33 71 36 166
Number of phenotypes 80 37 79 38 192
Number of cryptic and de novo 50 ss (%) 121 (35.0) 46 (13.3) 133 (38.4) 46 (13.3)
a 346 (100.0)
Number of unique 50ss (%) 114 (37.4) 44 (14.4) 101 (33.1) 46 (15.1) 305 (100.0)
Number of aberrant 50ss aﬀecting
terminal exons (%)
6 (50) 1 (8) 5 (42) 0 (0) 12 (4)
Median distance (nt) between authentic
and aberrant 50 splice sites
 46  56 49 16  7
Change in the reading frame for unique
aberrant 50 splice sites
b
0 45 16 41 7 109
+1 41 14 31 6 92
+2 28 13 27 2 70
aThe number of pseudoexons (cryptic exons) was 31 (9.0% of all reported aberrant 50ss and 10.1% of unique aberrant 50ss).
bThe distribution of the reading frame changes among unique aberrant 50ss (excl. cryptic exons) was not signiﬁcantly diﬀerent from that expected
(P=0.75).
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new 9-nt consensus, respectively, was highest for position
+5 (10.0), followed by position  1 (5.5) and +1 (4.1),
with an average ratio for all positions of 2.9.
The overall proportion of point mutations in patients
with aberrant 50ss that created the 50GT consensus was
 55% (Table 2). Newly created 50GT dinucleotides
were utilized by the spliceosome in 100% of the observed
cases. In contrast, although mutations generating 30AG
dinucleotides found in individuals with aberrant 30ss are
also present in about half of the cases, only  95% are
used in vivo, owing to the presence of ‘AG exclusion zones’
downstream of the BPS (36).
Tables 3 and 4 show the breakdown of point mutations
by nucleotide and by highly conserved positions of the
50ss consensus. Transitions (R-to-R or Y-to-Y, Y is
pyrimidine), which account for 62.5% of point mutations
in human disease genes (40), were found in 58.7% of
cases (Table 3). Comparison of mutations in highly
conserved positions of the 50ss consensus with those
expected based on previously published mononucleotide
mutation rates corrected for a number of confounding
eﬀects (40) suggested that the biased distribution is
unlikely to be fully explained by diﬀerential mutability
(Table 4; P=0.002 and 4.3 10
 7 for position +1
and +2, respectively). However, comparison with the
published dinucleotides rates that take into account
nearest-neighbour eﬀects no longer showed a signiﬁcant
P-value for position +1, consistent with a severe block of
splicing following mutations to any nucleotide (41).
Nevertheless, the distribution of point mutations at
position +2 was still unlikely to be fully explained by
diﬀerential mutabilities (Table 4, P=0.035), raising the
possibility that the observed under-representation of
+2C/A among cryptic 50ss may be attributed to higher
residual levels of accurately spliced pre-mRNAs with
50GC or 50GA dinucleotides. This would be consistent
with a previously observed +2T4+2C4+2A4+2G
Table 2. Summary of mutations leading to aberrant 50 splice sites
Location of cryptic or
de novo 50 splice sites
Exon Intron Both
Mutation In the 9-nt 50ss
consensus (cryptic)
Elsewhere
(‘de novo’)
In the 9-nt 50ss
consensus (cryptic)
Elsewhere
(‘de novo’)
All mutations
Number of deletions/duplications 7 4 10 5 26
Number of insertions 1 1 1 0 3
Number of complex mutations 0 0 2 0 2
Number of single-nucleotide substitutions 113 41 121 40 315
Wild-type nucleotide
A1 2 9 2 1 7 4 0
C 3 19 0 13 35
G 81 10 96 8 195
T 17 3 23 2 45
Mutated nucleotide
A 50 7 59 5 121
C 21 0 34 0 55
G 17 15 8 22 62
T 2 51 9 2 01 3 7 7
Number of GT-creating mutations (%) 65 (58) 21 (51) 60 (50) 28 (70) 174 (55)
Figure 1. Distribution of point mutations activating cryptic and/or
creating de novo 50ss. The x-axis shows the position of point mutations
in the 9-nucleotide 50ss consensus relative to the natural exon–intron
junctions (cryptic 50ss) or to the newly created exon–intron boundary
(de novo 50ss). The total number of point mutations at each position
of the 50ss consensus is shown on the y-axis. Grey bars denote the
number of cryptic 50ss; black bars denote the number of de novo 50ss.
The corresponding number of splicing mutations logged in the HGMD
was 11, 51, 320, 1445, 456, 163, 63, 347 and 46 for positions –3 through
+6, respectively (4).
Table 3. Breakdown by type of point mutations leading to
aberrant 50ss
Mutated nucleotide
AC G T
Wild-type
nucleotide
A – 1 (0.3) 35 (11.1) 4 (1.3)
C 2 (0.6) – 10 (3.2) 23 (7.3)
G 109 (34.6) 36 (11.4) – 50 (15.9)
T 10 (3.2) 18 (5.7) 17 (5.4) –
The number of point mutations for each nucleotide substitution is
followed by a percentage in parentheses.
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eﬃcient recognition of the 0.56% of mammalian introns
that have 50GC-30AG splice sites (44). Finally, the
distribution of point mutations at positions +1 and +2
and that for all splicing mutations in the Human Gene
Mutation Database (HGMD, http://www.hgmd.cf.ac.uk/
ac/index.php) were not signiﬁcantly diﬀerent (P=0.77
for position +1 and P=0.15 for position +2, Table 4).
This suggests that the mutation spectrum of the
50GT dinucleotide is similar for aberrant 50ss and exon
skipping events, which represent the bulk of HGMD
entries.
Frequent occurrenceof IVS+5Gmutations leading
tocryptic 50ss activation
Interestingly, all point mutations at position +5 of
authentic 50ss that activated cryptic 50ss were substitutions
of G, and not any other nucleotide (Figure 2), raising the
possibility that 50ss with +5G are more susceptible
to aberrant splice-site activation than 50ss with +5H
(non-G). However, assuming  78% occupancy of this
nucleotide in human 50ss (30) and a G/C substitution rate
of  70% derived from the HGMD data (40), the expected
number of +5H substitutions among authentic sites
whose mutation induces cryptic 50ss activation would
only be  4 in our dataset and not signiﬁcantly diﬀerent
from zero (P=0.1, Fisher’s exact test). A prominent
inﬂuence of diﬀerential mutability rates on the mutation
spectrum was also supported by the observed predomi-
nance of +5G4A transitions over transversions (Table 4).
In addition, the distribution of point mutations activating
cryptic 50ss was signiﬁcantly diﬀerent from that resulting
in de novo sites (P50.0001, Figure 1), with the latter
showing peaks in the most conserved positions +1 and
+2 and exclusive +5A4G transitions relative to new 50ss
that were located both in exons (45) or introns (46–48).
However, unique point mutations in the 9-nt consensus
logged in the HGMD (4) and in our sample (Figure 1)
had signiﬁcantly diﬀerent distributions (
2=27.7,
P=0.0005), with position +5 clearly overrepresented
in our dataset ( 22% versus  12%). This suggests that
the mutation spectra underlying cryptic 50ss activation
and exon skipping events are distinct.
A search for literature reports of point mutations that
produce either aberrant 50ss activation or exon skipping in
the same 50ss consensus revealed several discordant cases.
For example, the FBN1 substitution IVS46+5G4A
resulted in cryptic 50ss activation 33-nt downstream of
the authentic exon–intron junction (49), whereas the
IVS46+1G4A mutation caused exon 46 skipping (50).
Table 4. Number of single-nucleotide substitutions in highly conserved positions of the 50ss consensus that resulted in cryptic 50ss activation
Observed numbers for cryptic 50ss Expected
b
Location of cryptic 50 splice site Exon Intron Both
Point mutations at position IVS-1 13 20 33
 1G4A6 9 1 5
 1G4C4 9 1 3
 1G4T3 2 5
Point mutations at position IVS+1 50 41 91
+1G4A 30 27 57 (1024)
a 65.3 (60.0)
+1G4C 5 7 12 (273)
a 14.9 (12.2)
+1G4T 15 7 22 (411)
a 10.9 (18.8)
Point mutations at position IVS+2 15 19 34
+2T4C 4 9 13 (270)
a 22.5 (16.2)
+2T4G 8 6 14 (144)
a 6.0 (9.2)
+2T4A 2 4 6 (121)
a 5.5 (8.6)
Point mutations at position IVS+5 17 33 50
+5G4C 5 6 11 8.2
+5G4T 3 8 11 6.0
+z5G4A 9 19 28 35.9
aThe numbers in parentheses refer to all splicing mutations logged in the Human Gene Mutation Database (4). (http://www.hgmd.cf.ac.uk/ac/hoho2/
php).
bThe expected numbers were calculated from the relative mononucleotide mutability rates corrected for codon frequencies and other confounding
eﬀects (40). The expected numbers calculated from the previously published estimates of the relative substitution rates at the dinucleotide level (94)
are in parentheses in the same table column.
Figure 2. Cryptic 50ss generated by point mutations at position IVS+5.
(A) Nucleotide composition of cryptic 50ss activated by point mutations
at position +5 (upper panel) and their authentic counterparts (lower
panel). Sequence alignments of unique 50ss were analysed by a
pictogram utility available at: http://genes.mit.edu/pictogram.html.
The size of a pictogram character is proportional to the frequency of
each nucleotide, with the most frequent at the top. The percentage of
the most frequent nucleotide is shown above or below each panel.
4254 Nucleic Acids Research, 2007, Vol. 35, No. 13Similarly, the PTEN mutation IVS7+1G4A activated
a cryptic 50ss 75-nt downstream of the authentic
exon–intron boundary (51), whereas mutation
IVS7+2T4G in the same 50ss led exclusively to exon 7
skipping (52). In the latter case, IVS7+2T4G creates a
putative splicing silencer containing the AGGG motif,
which may prevent activation of the downstream cryptic
50ss, whereas IVS7+1G4A results in no consecutive Gs in
the 50ss consensus.
The presence of IVS+5H in authentic 50ss, which is not
predicted to base-pair with U1 or U6 snRNAs, was
proposed to be compensated by having G at the last
exon position (–1G) (53). The –1G can base-pair to U1
snRNA (30) and is almost completely conserved (97.5%)
in IVS+5H 50ss (53). The +5/ 1 association was
conﬁrmed with a large sample of homologous human-
mouse 50ss (30). In our dataset, only 18/35 (51%) of
unique authentic 50ss that were repressed by mutations of
IVS+5G in favour of a cryptic 50ss had -1G. This
percentage is signiﬁcantly (
2=10.9, P=0.001) lower
than for a large set of authentic 50ss (5142/6716,  77%).
In addition to position –1, adenosine –2 was less frequent
in our sample (31%; 11/24) as compared with 57% in
average 50ss (3830/6716, P=0.002), while the number of
uracils at position +6 was higher (25/35; 71% versus
3415/6716; 51%; 
2=5.1, P=0.02). These results are
consistent with previously described +5 dependencies
(30,53) and suggest that authentic 50ss that are susceptible
to IVS+5 mutations are less likely to make suﬃcient
contacts between positions –1/–2 and their interacting
factors, but may exhibit stronger putative base-
pairing interactions between U1/U6 snRNAs and
intron position +6.
Comparison of computational tools topredict
mutation-induced aberrant 50ss in vivo
Figure 3 shows the relative representation of each
nucleotide in the consensus sequence of aberrant 50ss
(upper panels) and the corresponding authentic sites
(lower panels). The consensus sequence of cryptic 50ss
had lower proportions of conserved residues than for
authentic 50ss at each position, except for the invariant
position +1 (Figure 3A). This diﬀerence was much
reduced in de novo 50ss, in which conserved nucleotides
at positions +3 through +6 had even higher frequencies
than those in their authentic counterparts (Figure 3B).
Sequence alignments of cryptic and de novo sites generated
in exons and introns are shown in Supplementary
Figures 1–3 together with their authentic counterparts.
Apart from G and #H between 50ss and U1 snRNA,
we used seven diﬀerent algorithms that predict utilization
of 50ss in multiple sequences and are publicly available
(Figure 4A,B). Cryptic 50ss had signiﬁcantly lower
scores with each algorithm, lower #H and higher G
than their authentic, wild-type counterparts. Cryptic
50ss were most eﬀectively discriminated from the authentic
sites by the ME model, followed by MDD and MM
algorithms. P-values obtained for the HBond and NN
scores were higher, even when we disregarded cryptic
50ss with non-canonical 50ss dinucleotides to obtain
the scores and replaced them with group means. All
these models clearly outperformed the matrix-based
prediction scores—S&S and WMM. The #H and G
values gave the poorest, albeit still signiﬁcant discrimina-
tion. The weakness of cryptic 50ss was well illustrated by a
shift of the #H peak frequency from seven in the authentic
counterparts to six in the cryptic 50ss (Figure 4C).
In contrast to cryptic 50ss, de novo 50ss were not
distinguished from their authentic counterparts by any
of the tested algorithms (Figure 4B). Although the number
of de novo 50ss was smaller than cryptic 50ss (Table 1),
random selections of the same number of cryptic 50ss and
their comparison with authentic sites gave consistently
signiﬁcant discrimination with several algorithms
(data not shown), indicating that computational predic-
tion of de novo 50ss is poor. However, newly created
50ss activating pseudoexons had higher ME scores than
the remaining de novo 50ss (8.66 3.00 versus 6.07 4.83,
P=0.0002) or the remaining intronic de novo 50ss
(Table 5, P=0.002). The corresponding 30ss of these
pseudoexons were slightly stronger than intronic de novo
30ss (ME scores 6.79 3.39 versus 5.24 4.50, P=0.04)
ascertained previously (36), but were not signiﬁcantly
diﬀerent from exonic de novo 30ss or their authentic
counterparts. Thus, activation of cryptic exons
through de novo 50ss use requires their high strength and
may be facilitated by intrinsically stronger decoy 30ss
across the newly formed exon.
We then tested each computational method separately
for aberrant 50ss in exons and introns (Table 5). Although
Figure 3. Sequence alignment of authentic and aberrant 50ss. Sequence
alignment of cryptic (A, upper panel) and de novo (B, upper panel)
50ss with their matching authentic counterparts (lower panels). The
nucleotide alignments were analysed by a pictogram utility as in
Figure 2. The size of a pictogram character is proportional to the
frequency of each nucleotide, with the most common at the top.
The percentage of the most frequent nucleotides in aberrant and
authentic sites is shown above and below each panel, respectively.
Nucleic Acids Research, 2007, Vol. 35, No. 13 4255cryptic 50ss in exons were best discriminated by the ME
scores, the lowest P-values for cryptic 50ss in introns were
achieved by the NN model. To test whether this could be
explained by having to disregard 50GC splice sites for
the NN method in both datasets and replace them by
group means, we recalculated the NN and ME scores
after removing 50GC splice sites, but we obtained a similar
result (P=1.2 10
 12 versus 1.0 10
 10, respectively).
Authentic counterparts of intronic de novo 50ss were
intrinsically weak and therefore less likely to challenge
newly created competitors. However, this was not evident
for exonic de novo sites, strongly suggesting that their
activation is more reliant on splicing regulatory sequences
in exons rather than on the intrinsic strength of the 50ss
consensus (Table 5). The overall performance of ME,
MDD, MM, HBond and NN models for the whole set
of aberrant 50ss was very similar, with minimal diﬀerences
in P-values. Finally, mutated authentic 50ss were on
average weaker than cryptic 50ss, conﬁrming an earlier
observation (11). Again, the lowest P-values of the
non-parametric test were observed for the ME model
(Table 5 and data not shown). Thus, as shown for 30ss
(36), the ME algorithm discriminated best both wild-type
and mutated authentic 50ss from cryptic 50ss (Table 5),
thus providing a method of choice for computational
prediction of aberrant splice sites.
Next, we carried out pair-wise comparisons of cryptic
and de novo 50ss with their authentic counterparts.
For each computational algorithm, we determined the
proportion of aberrant 50ss that showed equal or higher
scores than their respective wild-type authentic sites
(Figure 4D). This proportion was on average signiﬁcantly
higher for de novo 50ss than for cryptic 50ss and roughly
reﬂected the ability of each method to discriminate
between aberrant 50ss and their authentic counterparts.
The percentage of exonic cryptic 50ss with equal or higher
scores than their authentic counterparts was lowest for the
ME algorithm (10.5%). For intronic cryptic 50ss, the
same proportion was lowest for the NN method (14.4%,
Figure 4D). Using the best-performing algorithms,
 12.3% of cryptic 50ss were computationally stronger
than their wild-type authentic counterparts, yet they were
used in vivo only if the wild-type 50ss consensus was
inactivated or weakened by mutation. This underscores
the importance of factors that repress utilization of decoy
splice sites that are present in excess over natural sites
in the genome.
Importantly, the authentic counterparts of cryptic 50ss
were signiﬁcantly weaker than a large collection of 8415
natural 50ss (31), with the ME scores of 7.75 2.50 and
8.37 2.08, respectively (P=2 10
–6; Wilcoxon–Mann–
Whitney rank test). The distribution of #H in the
authentic counterparts of cryptic 50ss and natural 50ss
was also signiﬁcantly diﬀerent (P=0.02, 
2=13.5, 5 df
Figure 4. Comparison of computational tools to predict aberrant 50ss.
(A) cryptic 50ss, (B) de novo 50ss. S&S, Shapiro-Senapathy matrix score;
ME, Maximum Entropy model; MDD, maximal dependence decom-
position model; MM, First-order Markov model; WMM, weight matrix
model; Hbond, HBond score; #H, number of H bonds; G, predicted
free energy; NN, neural network model. P-values of the Wilcoxon–
Mann–Whitney rank tests comparing authentic and aberrant 50ss are
shown in parentheses for each algorithm. Pseudoexons were not
included in this comparison. (C), #H distribution in cryptic/de novo
50ss and their authentic counterparts. The expected #H distribution of
natural 50ss (closed diamonds) was calculated from the #H frequencies
observed for a large collection of human 50ss (31). (D), The proportion
of aberrant 50ss with equal or higher splice-site scores than their
authentic counterparts.
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(Figure 4C). The relative weakness of the authentic
counterparts of cryptic 50ss is consistent with the notion
that mutations in less conserved positions of stronger
50ss produce, on average, higher amounts of natural
transcripts and less severe phenotypes than identical
alterations in intrinsically weaker 50ss.
The predicted strengths of authentic sites that were
mutated at position +5 were signiﬁcantly lower than the
average authentic 50ss (ME scores 7.55 1.81 versus
8.37 2.08, P=0.0002) and also somewhat lower than
the authentic counterparts of all unique cryptic 50ss in our
dataset (7.55 1.81 versus 7.75 2.52), despite all having
+5G and a higher than average relative frequency of +6T
(Figure 2). Guanine at position +5 was proposed not to
be obligatory for 50ss selection if the two preceding
positions are purines (28); nevertheless 24/35 (69%) of
unique authentic 50ss with point mutations of +5G
had only purines at positions +3 and +4 and only a
single authentic counterpart had pyrimidines at both
positions.
Figure 5 shows a comparison of the ME scores
of cryptic and de novo 50ss by mutated position in the
authentic and new 50ss consensus, respectively. Cryptic
50ss had similar ME values irrespective of the location of
the point mutation (P40.05, F-test). In contrast, de novo
Table 5. Comparison of the strength of wild-type authentic, mutated and aberrant 50ss
Location of aberrant
50 splice sites
a
Exon Intron Both
Mutation In the 9-nt 50ss
consensus (cryptic)
Elsewhere
(‘de novo’)
In the 9-nt 50ss
consensus (cryptic)
Elsewhere
(’de novo’)
All mutations
Shapiro and Senapathy
matrix score (S&S)
AU (SD) 80.3 (8.3) 81.6 (9.4) 79.6 (9.1) 75.7 (7.4) 80.0 (8.8)
AB (SD) 70.8 (9.7) 77.7 (10.6) 74.3 (8.7) 81.7 (10.3) 74.6 (10.3)
P-value 4.8 10
 13 0.09 6.1 10
 6 0.008 7.6 10
 11
MU (SD) 65.4 (11.6) 81.6 (9.4) 63.1 (11.7) 75.7 (7.4) 67.7 (12.9)
Maximum entropy model (ME) AU (SD) 7.9 (2.2) 7.3 (2.9) 7.5 (2.9) 5.8 (2.9) 7.6 (2.6)
AB (SD) 3.2 (5.1) 6.1 (4.6) 4.6 (3.9) 7.8 (4.2) 4.8 (4.8)
P-value 3.8 10
 21 0.26 4.8 10
 10 0.003 3.6 10
 16
MU (SD) 0.6 (6.3) 7.3 (2.9) –0.8 (6.0) 5.8 (2.9) 1.4 (6.3)
Maximum-dependence decomposition
model (MDD)
AU (SD) 11.7 (2.5) 11.6 (2.9) 11.7 (2.7) 9.9 (2.6) 11.6 (2.7)
AB (SD) 7.9 (3.9) 10.4 (3.7) 8.9 (3.5) 11.8 (4.3) 9.2 (4.0)
P-value 1.0 10
 18 0.11 1.1 10
 9 0.001 1.0 10
 15
MU (SD) 4.6 (5.5) 11.6 (2.9) 3.7 (5.3) 9.9 (2.6) 5.7 (5.7)
First-order Markov model (MM) AU (SD) 7.5 (2.0) 7.5 (2.8) 7.2 (2.4) 6.1 (2.5) 7.3 (2.3)
AB (SD) 4.2 (3.6) 6.5 (3.0) 5.1 (2.5) 7.6 (2.7) 5.4 (3.3)
P-value 2.6 10
 19 0.13 1.4 10
 9 0.016 2.9 10
 16
MU (SD) 1.3 (4.7) 7.5 (2.8) 0.6 (4.4) 6.1 (2.5) 2.3 (4.9)
Weight matrix model (WMM) AU (SD) 7.2 (2.5) 7.6 (2.9) 6.9 (2.9) 6.0 (2.5) 7.1 (2.7)
AB (SD) 4.3 (3.2) 6.5 (3.1) 5.3 (2.7) 7.6 (2.9) 5.4 (3.2)
P-value 5.4 10
 12 0.09 6.2 10
 6 0.020 1.8 10
 10
MU (SD) 1.3 (4.5) 7.6 (2.9) 0.7 (4.5) 6.0 (2.5) 2.4 (4.9)
HBond score AU (SD) 14.7 (2.7) 14.6 (3.0) 14.2 (2.3) 13.3 (2.5) 14.4 (2.6)
AB (SD) 11.2 (2.8) 13.8 (3.2) 12.2 (2.5) 15.0 (3.1) 12.5 (3.1)
P-value 1.4 10
 18 0.17 2.0 10
 8 0.015 1.8 10
 15
Free energy (G) AU (SD)  5.8 (2.5)  5.8 (2.9)  5.5 (2.2)  5.7 (2.1)  5.7 (2.4)
AB (SD)  3.9 (2.3)  5.5 (2.2)  4.7 (2.4)  5.6 (2.2)  4.6 (2.4)
P-value 3.5 10
 9 0.23 9.3 10
 3 0.46 4.2 10
 7
MU (SD)  2.7 (2.2)  5.8 (2.9)  1.9 (1.9)  5.7 (2.1)  3.1 (2.7)
Number of H bonds (#H) AU (SD) 7.3 (1.2) 7.3 (1.1) 6.9 (1.0) 6.9 (1.0) 7.2 (1.1)
AB (SD) 6.1 (1.2) 7.0 (1.2) 6.8 (1.0) 7.0 (1.1) 6.6 (1.2)
P-value 5.7 10
 12 0.07 0.19 0.34 2.1 10
 8
MU (SD) 6.3 (1.3) 7.3 (1.1) 5.7 (1.3) 6.9 (1.0) 6.3 (1.4)
Neural network (NN) AU (SD) 0.78 (0.25) 0.74 (0.30) 0.82 (0.25) 0.55 (0.38) 0.78 (0.27)
AB (SD) 0.41 (0.35) 0.66 (0.39) 0.45 (0.38) 0.83 (0.31) 0.52 (0.39)
P-value 7.2 10
 16 0.15 2.4 10
 12 0.003 4.1 10
 15
Means and standard deviations (SD) of splice-site prediction scores for wild-type authentic (AU) and aberrant (AB) 50ss are followed by the P-values
(corrected for ties) of the Wilcoxon–Mann–Whitney rank tests comparing AB and AU. A small number of missing values for the HBond and NN
scores due to non-canonical nucleotides at positions +1 and +2 were treated as a group mean. P-values below 0.05 were considered signiﬁcant and
are shown in bold. The splice-site strength for authentic 50ss with mutations (MU) is shown only for algorithms that score non-canonical 50ss.
aPseudoexons were not included in this comparison.
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of the new 50ss consensus tended to be stronger, with
statistically signiﬁcant diﬀerences between de novo and
cryptic 50ss for the highly conserved positions +1 and +2.
In addition, we compared the ME scores of aberrant 50ss
with their respective counterparts (Figure 5). The authen-
tic counterparts of cryptic 50ss induced by point mutations
at positions +2 and +5 of natural sites were weaker
than the authentic counterparts of cryptic 50ss activated
by substitutions at position +1 (7.24 1.93 for position
+2 and 7.22 2.06 for position +5 versus 8.34 2.21
for position +1, P50.01 for both comparisons). This
is consistent with the notion that mutations at less
conserved positions of authentic 50ss are less likely to
completely inactivate the 50ss and result in recognizable
phenotypes than mutations at position +1. The authentic
counterparts of de novo sites induced by mutations at
position +1 were signiﬁcantly weaker than the authentic
counterparts of cryptic 50ss induced by mutations at
the same position (6.33 3.39 versus 8.34 2.21). The
number of mutations for the remaining positions of the
50ss consensus was too small for meaningful comparisons.
The average intrinsic strength of aberrant and authentic
50ss in each category is schematically summarized as the
mean ME score in Figure 6.
Taken together, cryptic 50ss generated in vivo were
best predicted by models that accommodate nucleotide
dependencies in the 50ss, particularly by the ME algo-
rithm, which takes into account non-adjacent positions
(Figure 4A). Discrimination of exonic cryptic 50ss from
their authentic counterparts was more eﬃcient than that
for intronic cryptic 50ss, because the former category of
aberrant 50ss was weaker than the latter (P=0.02), for
which the NN model gave the best performance (Table 5).
Computational discrimination of de novo 50ss and their
authentic counterparts was poor (Figure 4B) as de novo
50ss were, on average, stronger than cryptic 50ss (Table 5),
particularly when generated by point mutations in highly
conserved intronic positions of the new 50ss consensus
(Figure 5). The intrinsic strength of exonic de novo
50ss could not be distinguished from their authentic sites
at all, pointing to the importance of exonic regulatory
sequences in their selection. Finally, the authentic
counterparts of aberrant (both cryptic and de novo)5 0ss
were weaker than a large collection of human
50ss, highlighting the practical importance of ranking
splice sites in human disease genes using eﬃcient
computational tools. We propose that their systematic
categorization may facilitate identiﬁcation of intronic
mutations or polymorphisms that aﬀect pre-mRNA
splicing, improve the interpretation of unknown altera-
tions and, ultimately, increase the cost-eﬀectiveness of
mutation screening.
DBASS5
The DBASS5 (http://www.dbass.org.uk/5) provides access
to the database of aberrant 50ss through the search option
(Supplemental Figure 4A). DBASS5 can be searched by
phenotype, gene, mutation, location of aberrant 50ss and
their distance from authentic 50ss. If more than one
database entry is found, the user can manually choose the
details page (Supplemental Figure 4B), which shows
nucleotide sequences ﬂanking the authentic and aberrant
50ss, the estimated strength of both authentic and aberrant
50ss and literature references with a PubMed hyperlink.
DBASS5 visitors can register to obtain regular updates
by email and can submit published data through
a submission tool. Potential applications of DBASS5
include optimization of splice-site prediction algorithms,
leading to improved prediction of aberrant 50ss, identiﬁca-
tion of genes and gene segments frequently involved
in aberrant splice-site activation, detection of splicing
mutations in a gene or phenotype of interest and selection
of in vitro models for studying basic mechanisms of
50ss utilization.
Figure 5. Splice-site strength of authentic and aberrant 50ss by position
of the point mutation. The ME scores of cryptic and de novo 50ss
induced by point mutations at positions -2 through +6 relative to the
authentic and the new intron–exon boundary, respectively, are followed
by the ME scores of their authentic counterparts. Unlike the authentic
counterparts, aberrant 50ss included pseudoexon sequences. Error bars
represent standard deviations (except for a single value entry for
authentic counterparts of de novo 50ss generated by a mutation at
position +5).
Figure 6. Summary of the splice-site strength by category of aberrant
50ss. (A) cryptic 50ss in introns (upper panel) and exons (lower panel);
(B) de novo 50ss in introns (upper panel) and exons (lower panel).
The average ME scores are shown next to the corresponding category
of 50ss. Exons are represented by boxes, introns are represented by
lines. A cryptic exon is denoted by a black box. Canonical and aberrant
RNA products are shown above and below the primary transcript,
respectively. Mutations in the 9-nt consensus of authentic 50ss (A) or
elsewhere (B) are schematically represented by stars.
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The database ofmutation-induced aberrantsplice sites
This report presents the ﬁrst comprehensive and publicly
available database of aberrant splice sites in human
disease genes. Together with a recently described database
of aberrant 30ss (36), this combined resource now contains
over 600 unique mutations that create or activate a total
of 562 aberrant splice sites.
The overall number of reported aberrant 50ss was higher
than aberrant 30ss, consistent with sequence limitations
imposed by additional signal sequences upstream of 30ss
(BPS and PPT) that are important for recognition of splice
acceptor sites. The relative ratio of non-repetitive aberrant
50ss (n=305) and 30ss (n=257) [(36) and
I.V.,(unpublished data)], was smaller than that reported
for unique splicing mutations in the HGMD that were
arbitrarily selected to reside in 5 exonic and 15 intronic
nucleotides adjacent to natural splice sites (4), i.e, 1.2
versus 1.5, respectively. The lower ratio might reﬂect a
reporting bias towards mutations closer to authentic splice
sites for exon skipping events. Mutations located
upstream of intronic splicing signals that are required
for 30ss selection could not be detected in many published
mutation reports, because these regions were ampliﬁed
only for a subset of introns or were not scanned at all. In
addition, the lower ratio could be due to an under-
representation of mutations leading to de novo splice sites
in the HGMD as compared to our dataset. Also, the
availability of suitable decoy splice sites near mutated sites
is likely to determine if the outcome of a splicing mutation
is exon skipping or aberrant splice-site activation (4).
The higher number of cryptic than de novo 50ss (Table 1)
can, probably to a large extent, be explained by a
detection bias of DNA-based mutation screening,
a method used to identify most aberrant 50ss in this
dataset, towards coding regions and ﬂanking intronic
sequences. As explained above, classiﬁcation of aberrant
50ss as cryptic and de novo 50ss may occasionally be vague,
but DBASS5 contains only two ambiguous examples
(54,55). Both cases were induced by G+1-to-T+1 substitu-
tions in 50ss that had G at position  1, creating a new
50GT 1-nt upstream of the authentic 50’ss. Both cases were
classiﬁed as cryptic 50ss in our analysis. The rarity of such
cases conﬁrms the validity of the previously proposed (11)
categorization of aberrant 50ss.
Mutation pattern ofaberrant 50ss
The most frequent point mutations that activated aberrant
50ss were purine transitions, accounting for 45.7% cases
(11.1% A4G and 34.6% G4A mutations; Table 3).
This ﬁgure seems to be somewhat lower (P=0.08) than
the  54% (113/211) observed for aberrant 30ss (36),
probably due to a higher prevalence of transitions in the
30YAG than those in the 50ss consensus. Cryptic 50ss
resulted from point mutations in each nucleotide of the
9-nt consensus except for position –3, consistent with this
position being the least conserved. However, position –3
has previously been implicated in pathological exon
skipping in well-documented cases (56–59), suggesting
that –3 substitutions in weak 50ss are also likely to result in
aberrant 50ss, although these cases must be rare and
aberrant splicing and putative phenotypic manifestations
could be subtle.
As for positions adjacent to the 9-nt 50ss consensus,
each of the reported single-base substitutions at intron
positions +7 and +8 created new 50GT dinucleotides
in situ that were used in vivo (60,61). Despite position +7
exhibiting a predominance of purines after several rounds
of functional 50ss selection experiments (28), point
mutations downstream of the 50ss consensus resulting
in activation of cryptic 50ss have thus far not been
reported. Among upstream substitutions in DBASS5,
we found only a single case of an exonic de novo 50ss
generated by a C4T transition 11-nt upstream of an
authentic 50ss (62), consistent with a disruption of exonic
splicing regulatory sequences.
Are point mutations at any position of the 50ss
consensus sequence particularly prone to aberrant 50ss
activation? As observed for mutations in the HGMD (4),
position +1 led the frequency table in our dataset,
with 49.8% and 39.4% mutations observed in the two
studies, respectively (Figure 1). However, the overall
distribution of mutations within the 50ss consensus was
signiﬁcantly diﬀerent between the two. In particular,
the proportion of mutations at position +5 was almost
twice as high among cryptic 50ss than in the HGMD
[Figure 1 and ref. (4)]. For unique point mutations
leading to cryptic 50ss activation, this position was in the
second place and position +2 in the third, whereas
this order was opposite for unique mutations in the
HGMD (50 and 34 mutations versus 347 and 456,
respectively; P=0.004).
G at position +5 is nearly invariant in Saccharomyces
cerevisiae (63). In contrast, +5G is present in only  88%
of S. pombae introns (64) and  78% of human introns
(30), indicating that relief from the absolute requirement
for G was an ancient evolutionary event. Comparison of
exonized and non-exonized intronic Alu repeats revealed
a higher number of +5Gs in exonized sequences (65).
Mutations at position +5 have resulted in frequent
activation of cryptic 50ss both in yeasts (66–69) and
humans (Figure 1, all references available at: http://
www.dbass.org.uk). Our study is the ﬁrst to provide
statistical evidence that this position is important for
distinct aberrant splicing outcomes. DBASS5 gives many
examples of natural 50ss in which diﬀerent point mutations
resulted in the same cryptic 50ss. Similarly, there are
numerous cases in the literature of identical exon
skipping events caused by diﬀerent point mutations in
the same 50ss. The identiﬁcation of several exceptions in
humans using the DBASS5 and HGMD data (49–52) is
consistent with an earlier observation in S. cerevisiae,
namely that cryptic 50ss activation by +5G4A mutation
was not replicated for another 50ss point mutation in the
same intron (67). These rare examples may provide
important insights into the requirements for activation
of aberrant 50ss, as opposed to exon skipping events.
In addition to the local sequence context, the frequent
occurrence of +5G4A substitutions underlying aberrant
50ss activation (Figure 1 and Table 3) can be explained
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More dramatic splicing defects for +5G4A transitions
than +5G transversions were found in S. cerevisiae (69).
In contrast, each IVS1+5G4H mutation in the human
proinsulin gene promoted activation of a competing
decoy 50ss 26nt downstream of the authentic 50ss to the
same extent, irrespective of the substituting nucleotide
[(7); J.K. and I.V., unpublished data], consistent with a
position eﬀect.
What interaction(s) at position +5 is crucial for
aberrant 50ss activation? Authentic 50ss in which mutation
at position +5 generated cryptic 50ss had a high
proportion of +5G+6T (Figure 2). Interestingly,
the +5G+6T dinucleotide signiﬁes the most frequent
location for alternative 50ss across several species,
and this preference was suggested to result from U1
binding rather than U6 binding (70). However, compen-
satory mutations in U1 snRNA that restore base-pairing
with the mutated intron frequently fail to suppress
aberrant splicing, suggesting that position +5 is engaged
in additional interactions (28,71–74). Interaction of U6
snRNA with the 50ss (75) at intron position +5 (76)
was partially suppressed by U6 mutations predicted to
increase base-pairing (77,78). Although the 50 ss has very
limited complementarity to the U6 ACAGAG motif, this
interaction seems to be important for accurate 50ss
selection also in mammals (78–80), albeit not in all
systems (81). In addition, cryptic splice sites have been
induced by co-expression of splicing reporters with
mutated snRNAs, including U1 (82), U5 (83,84) and
U6 (77–79,85), both in yeast (77,82,83,85) and mammals
(78,79,84).
As U1 snRNP binds sequences that are not used as
50ss and is present in excess over U6, sequential occupancy
by both snRNPs may be absolutely essential for accurate
50ss utilization (86,87). This would be consistent with
rate-limiting U6 snRNA interactions with the pre-mRNA
observed for U1-independent splicing (78) and loose
requirements for U1 binding in numerous introns
(28,71,72,74). Mutations of IVS+5G that resulted in
cryptic 50ss occurred in relatively weak authentic 50ss
and they are likely to further reduce U1 binding so that it
may no longer be suﬃcient for accurate 50ss recognition.
U6/U4.U5 snRNP would then bind to nearby pseudo-sites
that are, on average, intrinsically stronger than
the mutated authentic 50ss [Table 5 and ref. (11)]. The
strength of predicted base-pairing interactions at positions
+5 and +6 in the authentic counterparts (Figure 2)
may hamper the transfer of these 50ss from U1 to U6.
In fact, strong 50ss were reported to be inhibitory in
S. cerevisiae, potentially delaying the release of U1 and
productive interactions with U6 (28), although extended
complementarity between U1 snRNA and a human
immunodeﬁciency virus 1 donor site did not inhibit
splicing (81). Mutations that destabilized a yeast 50ss/U6
duplex improved the second step of splicing and hyper-
stabilization of the 50ss/U6 interaction had the opposite
eﬀect, suggesting that changing the stability of these
interactions alters the equilibrium between the ﬁrst and
second step conformations (88). Suppression of 50ss
mutations by U6 in a hybrid reporter was more eﬃcient
when U1 could pair nearby than when pairing was
restored further away (79). In addition, position +5
may directly interact with U6 residues that base pair to the
BPS recognition region of U2 (89) as well as with other
splicing factors, such as PRP8 (90,91). Finally, sequential
recognition of position +5 is likely to require contacts
with exon-bound factors that may substitute for U1
interactions (92,93), and that may be essential for
spliceosome assembly at authentic 50ss and contribute to
the observed high number of cryptic sites as compared to
de novo 50ss (Figure 1 and Table 1).
In summary, we have shown that cryptic 50ss in
human disease genes are best predicted by computational
methods that accommodate nucleotide dependencies
and not by methods employing only nucleotide
frequency matrices. Discrimination of intronic cryptic
50ss from their authentic counterparts was less eﬀective
than for exonic cryptic 50ss, as the former were intrinsi-
cally stronger than the latter. Computational prediction
of exonic de novo 50ss was poor, suggesting that their
activation in vivo critically depends on exonic splicing
enhancers or silencers, rather than on the strength of the
50ss consensus, and that improved algorithms for
their prediction will need to accommodate auxiliary
splicing sequences. The authentic counterparts of both
de novo and cryptic 50ss were weaker than the average
human 50ss, highlighting the practical importance of
ranking splice sites in disease genes to improve detection
of splicing mutations. The mutation spectra of cryptic
and de novo 50ss were distinct and diﬀered also from that
underlying exon skipping events, implicating point
mutations at position +5 in frequent activation of cryptic
50ss. Finally, the development of an online database
of aberrant 50ss will facilitate detection of introns
and exons frequently involved in aberrant splicing,
identiﬁcation of auxiliary sequences that control
selection of aberrant splice sites, ﬁne-tuning of splice-
site prediction algorithms, identiﬁcation of splicing
mutations, as well as studies of the basic mechanisms of
splice-site selection.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
ACKNOWLEDGEMENTS
This work was supported by the Juvenile Diabetes
Research Foundation International (1-2006-263),
Telethon Onlus Foundation (GGP02453 and
GGP06147), FIRB (RBNE01W9PM), and by the EC
grant EURASNET-LSHG-CT-2005-518238. A.R.K.
acknowledges support from NIH grant GM42699.
We thank S. Mills, R. Sood, P. Gibbs and T. Bryant
for technical help. Funding to pay the Open Access
publication charges for this article was shared equally by
the above funding sources.
Conﬂict of interest statement. None declared.
4260 Nucleic Acids Research, 2007, Vol. 35, No. 13REFERENCES
1. Cooper,D.N. and Krawczak,M. (1993) Human Gene Mutation BIOS
Scientiﬁc Publishers, Oxford.
2. Teraoka,S.N., Telatar,M., Becker-Catania,S., Liang,T., Onengut,S.,
Tolun,A., Chessa,L., Sanal,O ¨ ., Bernatowska,E. et al. (1999)
Splicing defects in the ataxia-telangiectasia gene, ATM:
underlying mutations and consequences. Am. J. Hum. Genet., 64,
1617–1631.
3. Ars,E., Serra,E., Garcia,J., Kruyer,H., Gaona,A., Lazaro,C. and
Estivill,X. (2000) Mutations aﬀecting mRNA splicing are the most
common molecular defects in patients with neuroﬁbromatosis type
1. Hum. Mol. Genet., 9, 237–247.
4. Krawczak,M., Thomas,N.S., Hundrieser,B., Mort,M., Wittig,M.,
Hampe,J. and Cooper,D.N. (2007) Single base-pair substitutions in
exon-intron junctions of human genes: nature, distribution, and
consequences for mRNA splicing. Hum. Mutat., 28, 150–158.
5. Cooper,T.A. and Mattox,W. (1997) The regulation of splice-site
selection, and its role in human disease. Am. J. Hum. Genet., 61,
259–266.
6. Nissim-Raﬁnia,M. and Kerem,B. (2002) Splicing regulation as a
potential genetic modiﬁer. Trends Genet., 18, 123–127.
7. Kra ´ lovic ˘ ova ´ ,J., Gaunt,T.R., Rodriguez,S., Wood,P.J., Day,I.N.M.
and Vor˘echovsky ´ ,I. (2006) Variants in the human insulin gene that
aﬀect pre-mRNA splicing: is -23HphI a functional single nucleotide
polymorphism at IDDM2? Diabetes, 55, 260–264.
8. Pagani,F. and Baralle,F.E. (2004) Genomic variants in exons and
introns: identifying the splicing spoilers. Nat. Rev. Genet., 5,
389–396.
9. Nakai,K. and Sakamoto,H. (1994) Construction of a novel
database containing aberrant splicing mutations of mammalian
genes. Gene, 141, 171–177.
10. Baralle,D. and Baralle,M. (2005) Splicing in action: assessing
disease causing sequence changes. J. Med. Genet., 42, 737–748.
11. Roca,X., Sachidanandam,R. and Krainer,A.R. (2003) Intrinsic
diﬀerences between authentic and cryptic 50 splice sites.
Nucleic Acids Res., 31, 6321–6333.
12. Kra ´ lovic ˘ ova ´ ,J., Christensen,M.B. and Vor˘echovsky ´ ,I. (2005)
Biased exon/intron distribution of cryptic and de novo 30 splice sites.
Nucleic Acids Res., 33, 4882–4898.
13. Cartegni,L., Chew,S.L. and Krainer,A.R. (2002) Listening to silence
and understanding nonsense: exonic mutations that aﬀect splicing.
Nat. Rev. Genet., 3, 285–298.
14. Fairbrother,W.G., Yeh,R.F., Sharp,P.A. and Burge,C.B. (2002)
Predictive identiﬁcation of exonic splicing enhancers in human
genes. Science, 297, 1007–1013.
15. Wang,Z., Xiao,X., Van Nostrand,E. and Burge,C.B. (2006) General
and speciﬁc functions of exonic splicing silencers in splicing control.
Mol. Cell, 23, 61–70.
16. Zhang,X.H. and Chasin,L.A. (2004) Computational deﬁnition of
sequence motifs governing constitutive exon splicing. Genes Dev.,
18, 1241–1250.
17. Buratti,E., Baralle,M. and Baralle,F.E. (2006) Defective splicing,
disease and therapy: searching for master checkpoints in exon
deﬁnition. Nucleic Acids Res., 34, 3494–3510.
18. Roca,X., Sachidanandam,R. and Krainer,A.R. (2005) Determinants
of the inherent strength of human 50 splice sites. RNA, 11, 683–698.
19. Spena,S., Tenchini,M.L. and Buratti,E. (2006) Cryptic splice site
usage in exon 7 of the human ﬁbrinogen Bb-chain gene is regulated
by a naturally silent SF2/ASF binding site within this exon. RNA,
12, 948–958.
20. Buratti,E. and Baralle,F.E. (2004) Inﬂuence of RNA secondary
structure on the pre-mRNA splicing process. Mol. Cell. Biol., 24,
10505–10514.
21. Kornblihtt,A.R. (2005) Promoter usage and alternative splicing.
Curr. Opin. Cell Biol., 17, 262–268.
22. Singh,N.N., Singh,R.N. and Androphy,E.J. (2007) Modulating role
of RNA structure in alternative splicing of a critical exon in the
spinal muscular atrophy genes. Nucleic Acids Res., 35, 371–389.
23. Buratti,E., Baralle,M., De Conti,L., Baralle,D., Romano,M.,
Ayala,Y.M. and Baralle,F.E. (2004) hnRNP H binding at the
50 splice site correlates with the pathological eﬀect of two intronic
mutations in the NF-1 and TSHb genes. Nucleic Acids Res., 32,
4224–4236.
24. Shapiro,M.B. and Senapathy,P. (1987) RNA splice junctions of
diﬀerent classes of eukaryotes: sequence statistics and functional
implications in gene expression. Nucleic Acids Res., 15, 7155–7174.
25. Senapathy,P., Shapiro,M.B. and Harris,N.L. (1990) Splice
junctions, branch point sites, and exons: sequence statistics,
identiﬁcation, and applications to genome project. Methods
Enzymol., 183, 252–278.
26. Brunak,S., Engelbrecht,J. and Knudsen,S. (1991) Prediction of
human mRNA donor and acceptor sites from the DNA sequence.
J. Mol. Biol., 220, 49–65.
27. Reese,M.G., Eeckman,F.H., Kulp,D. and Haussler,D. (1997)
Improved splice site detection in Genie. J. Comput. Biol., 4,
311–323.
28. Lund,M. and Kjems,J. (2002) Deﬁning a 50 splice site by functional
selection in the presence and absence of U1 snRNA 50 end. RNA, 8,
166–179.
29. Freund,M., Asang,C., Kammler,S., Konermann,C.,
Krummheuer,J., Hipp,M., Meyer,I., Gierling,W., Theiss,S. et al.
(2003) A novel approach to describe a U1 snRNA binding site.
Nucleic Acids Res., 31, 6963–6975.
30. Carmel,I., Tal,S., Vig,I. and Ast,G. (2004) Comparative analysis
detects dependencies among the 50 splice-site positions. RNA, 10,
828–840.
31. Yeo,G. and Burge,C.B. (2004) Maximum entropy modeling of short
sequence motifs with applications to RNA splicing signals.
J. Comput. Biol., 11, 377–394.
32. Thanaraj,T.A. (2000) Positional characterisation of false
positives from computational prediction of human splice sites.
Nucleic Acids Res., 28, 744–754.
33. Busslinger,M., Moschonas,N. and Flavell,R.A. (1981)
b
+ thalassemia: aberrant splicing results from a single point
mutation in an intron. Cell, 27, 289–298.
34. Felber,B.K., Orkin,S.H. and Hamer,D.H. (1982)
Abnormal RNA splicing causes one form of a thalassemia. Cell, 29,
895–902.
35. Treisman,R., Proudfoot,N.J., Shander,M. and Maniatis,T. (1982)
A single-base change at a splice site in a b
0-thalassemic gene causes
abnormal RNA splicing. Cell, 29, 903–911.
36. Vor˘echovsky ´ ,I. (2006) Aberrant 30 splice sites in human disease
genes: mutation pattern, nucleotide structure and comparison of
computational tools that predict their utilization. Nucleic Acids
Res., 34, 4630–4641.
37. Burge,C.B. (1998) In Salzberg,S.L., Searls,D.B. and Kasif,S. (eds),
Computational methods in molecular biology, Elsevier Science,
Amsterdam, pp. 129–164.
38. Staden,R. (1984) Computer methods to locate signals in nucleic acid
sequences. Nucleic Acids Res., 12, 505–519.
39. Markham,N.R. and Zuker,M. (2005) DINAMelt web server for
nucleic acid melting prediction. Nucleic Acids Res., 33, W577–581.
40. Krawczak,M., Ball,E.V. and Cooper,D.N. (1998) Neighboring-
nucleotide eﬀects on the rates of germ-line single-base-pair
substitution in human genes. Am. J. Hum. Genet., 63, 474–488.
41. Deirdre,A., Scadden,J. and Smith,C.W. (1995) Interactions
between the terminal bases of mammalian introns are retained in
inosine-containing pre-mRNAs. EMBO J., 14, 3236–3246.
42. Ruis,B.L., Kivens,W.J. and Siliciano,P.G. (1994) The interaction
between the ﬁrst and last intron nucleotides in the second step of
pre-mRNA splicing is independent of other conserved intron
nucleotides. Nucleic Acids Res., 22, 5190–5195.
43. Aebi,M., Hornig,H. and Weissmann,C. (1987) 50 cleavage site in
eukaryotic pre-mRNA splicing is determined by the overall 50 splice
region, not by the conserved 50 GU. Cell, 50, 237–246.
44. Burset,M., Seledtsov,I.A. and Solovyev,V.V. (2001) SpliceDB:
database of canonical and non-canonical mammalian splice sites.
Nucleic Acids Res., 29, 255–259.
45. O0Driscoll,M., Ruiz-Perez,V.L., Woods,C.G., Jeggo,P.A. and
Goodship,J.A. (2003) A splicing mutation aﬀecting expression of
ataxia-telangiectasia and Rad3-related protein (ATR) results in
Seckel syndrome. Nat. Genet., 33, 497–501.
46. McConville,C.M., Stankovic,T., Byrd,P.J., McGuire,G.M.,
Yao,Q.Y., Lennox,G.G. and Taylor,M.R. (1996) Mutations
associated with variant phenotypes in ataxia-telangiectasia.
Am. J. Hum. Genet., 59, 320–330.
Nucleic Acids Research, 2007, Vol. 35, No. 13 426147. Rathmann,M., Bunge,S., Beck,M., Kresse,H., Tylki-Szymanska,A.
and Gal,A. (1996) Mucopolysaccharidosis type II (Hunter
syndrome): mutation ‘‘hot spots’’ in the iduronate-2-sulfatase gene.
Am. J. Hum. Genet., 59, 1202–1209.
48. Tuﬀery-Giraud,S., Saquet,C., Chambert,S. and Claustres,M. (2003)
Pseudoexon activation in the DMD gene as a novel mechanism for
Becker muscular dystrophy. Hum. Mutat., 21, 608–614.
49. Hutchinson,S., Wordsworth,B.P. and Handford,P.A. (2001) Marfan
syndrome caused by a mutation in FBN1 that gives rise to cryptic
splicing and a 33 nucleotide insertion in the coding sequence.
Hum. Genet., 109, 416–420.
50. Nijbroek,G., Sood,S., McIntosh,I., Francomano,C.A., Bull,E.,
Pereira,L., Ramirez,F., Pyeritz,R.E. and Dietz,H.C. (1995)
Fifteen novel FBN1 mutations causing Marfan syndrome
detected by heteroduplex analysis of genomic amplicons.
Am. J. Hum. Genet., 57, 8–21.
51. Celebi,J.T., Wanner,M., Ping,X.L., Zhang,H. and Peacocke,M.
(2000) Association of splicing defects in PTEN leading to exon
skipping or partial intron retention in Cowden syndrome.
Hum. Genet., 107, 234–238.
52. Tsou,H.C., Ping,X.L., Xie,X.X., Gruener,A.C., Zhang,H., Nini,R.,
Swisshelm,K., Sybert,V., Diamond,T.M. et al. (1998) The genetic
basis of Cowden0s syndrome: three novel mutations in PTEN/
MMACI/TEP1. Hum. Genet., 102, 467–473.
53. Burge,C. and Karlin,S. (1997) Prediction of complete gene
structures in human genomic DNA. J. Mol. Biol., 268, 78–94.
54. Attanasio,C., de Moerloose,P., Antonarakis,S.E., Morris,M.A. and
Neerman-Arbez,M. (2001) Activation of multiple cryptic donor
splice sites by the common congenital aﬁbrinogenemia mutation,
FGA IVS4+1G4T. Blood, 97, 1879–1881.
55. Cavalcanti,D.P., Matejas,V., Luquetti,D., Mello,M.F. and
Zenker,M. (2006) Fraser and Ablepharon macrostomia phenotypes:
Concurrence in one family and association with mutated FRAS1.
Am. J. Med. Genet. A, 143, 241–247.
56. Wang,X., Poh-Fitzpatrick,M., Carriero,D., Ostasiewicz,L., Chen,T.,
Taketani,S. and Piomelli,S. (1993) A novel mutation in
erythropoietic protoporphyria: an aberrant ferrochelatase
mRNA caused by exon skipping during RNA splicing.
Biochim. Biophys. Acta, 1181, 198–200.
57. Williamson,D., Brown,K.P., Langdown,J.V. and Baglin,T.P. (1995)
Haemoglobin Dhofar is linked to the codon 29C4T (IVS-1nt-3)
splice mutation which causes b
+ thalassaemia. Br. J. Haematol., 90,
229–231.
58. Chao,H.K., Hsiao,K.J. and Su,T.S. (2001) A silent mutation
induces exon skipping in the phenylalanine hydroxylase gene in
phenylketonuria. Hum. Genet., 108, 14–19.
59. Aretz,S., Uhlhaas,S., Sun,Y., Pagenstecher,C., Mangold,E.,
Caspari,R., Moslein,G., Schulmann,K., Propping,P. et al. (2004)
Familial adenomatous polyposis: aberrant splicing due to
missense or silent mutations in the APC gene. Hum. Mutat., 24,
370–380.
60. Lo ´ pez-Bigas,N., Rabionet,R., de Cid,R., Govea,N., Gasparini,P.,
Zelante,L., Arbones,M.L. and Estivill,X. (1999) Splice-site mutation
in the PDS gene may result in intrafamilial variability for deafness
in Pendred syndrome. Hum. Mutat., 14, 520–526.
61. Sidwell,R.U., Sandison,A., Wing,J., Fawcett,H.D., Seet,J.E.,
Fisher,C., Nardo,T., Stefanini,M., Lehmann,A.R. et al. (2006)
A novel mutation in the XPA gene associated with unusually mild
clinical features in a patient who developed a spindle cell melanoma.
Br. J. Dermatol., 155, 81–88.
62. Yamada,T., Tachibana,A., Shimizu,T., Mugishima,H., Okubo,M.
and Sasaki,M.S. (2000) Novel mutations of the FANCG gene
causing alternative splicing in Japanese Fanconi anemia.
J. Hum. Genet., 45, 159–166.
63. Spingola,M., Grate,L., Haussler,D., Ares, and M. Jr. (1999)
Genome-wide bioinformatic and molecular analysis of introns in
Saccharomyces cerevisiae. RNA, 5, 221–234.
64. Ast,G. (2004) How did alternative splicing evolve? Nat. Rev. Genet.,
5, 773–782.
65. Sorek,R., Lev-Maor,G., Reznik,M., Dagan,T., Belinky,F.,
Graur,D. and Ast,G. (2004) Minimal conditions for exonization of
intronic sequences: 50 splice site formation in Alu exons. Mol. Cell,
14, 221–231.
66. Parker,R. and Guthrie,C. (1985) A point mutation in the conserved
hexanucleotide at a yeast 50 splice junction uncouples recognition,
cleavage, and ligation. Cell, 41, 107–118.
67. Jacquier,A., Rodriguez,J.R. and Rosbash,M. (1985) A quantitative
analysis of the eﬀects of 50 junction and TACTAAC box mutants
and mutant combinations on yeast mRNA splicing. Cell, 43,
423–430.
68. Fouser,L.A. and Friesen,J.D. (1986) Mutations in a yeast intron
demonstrate the importance of speciﬁc conserved nucleotides for the
two stages of nuclear mRNA splicing. Cell, 45, 81–93.
69. Lesser,C.F. and Guthrie,C. (1993) Mutational analysis of
pre-mRNA splicing in Saccharomyces cerevisiae using a sensitive
new reporter gene, CUP1. Genetics, 133, 851–863.
70. Dou,Y., Fox-Walsh,K.L., Baldi,P.F. and Hertel,K.J. (2006)
Genomic splice-site analysis reveals frequent alternative splicing
close to the dominant splice site. RNA, 12, 2047–2056.
71. Se ´ raphin,B., Kretzner,L. and Rosbash,M. (1988) A U1
snRNA:pre-mRNA base pairing interaction is required early in
yeast spliceosome assembly but does not uniquely deﬁne the
50 cleavage site. EMBO J., 7, 2533–2538.
72. Siliciano,P.G. and Guthrie,C. (1988) 50 splice site selection in yeast:
genetic alterations in base-pairing with U1 reveal additional
requirements. Genes Dev., 2, 1258–1267.
73. Se ´ raphin,B. and Rosbash,M. (1990) Exon mutations uncouple 50
splice site selection from U1 snRNA pairing. Cell, 63, 619–629.
74. Cohen,J.B., Snow,J.E., Spencer,S.D. and Levinson,A.D. (1994)
Suppression of mammalian 50 splice-site defects by U1 small nuclear
RNAs from a distance. Proc. Natl Acad. Sci. USA, 91,
10470–10474.
75. Sawa,H. and Shimura,Y. (1992) Association of U6 snRNA with the
50-splice site region of pre-mRNA in the spliceosome. Genes Dev., 6,
244–254.
76. Wassarman,D.A. and Steitz,J.A. (1992) Interactions of small
nuclear RNA0s with precursor messenger RNA during in vitro
splicing. Science, 257, 1918–1925.
77. Kandels-Lewis,S. and Seraphin,B. (1993) Involvement of U6
snRNA in 50 splice site selection. Science, 262, 2035–2039.
78. Crispino,J.D. and Sharp,P.A. (1995) A U6 snRNA:pre-mRNA
interaction can be rate-limiting for U1-independent splicing.
Genes Dev., 9, 2314–2323.
79. Hwang,D.Y. and Cohen,J.B. (1996) U1 snRNA promotes the
selection of nearby 50 splice sites by U6 snRNA in mammalian cells.
Genes Dev., 10, 338–350.
80. Brackenridge,S., Wilkie,A.O. and Screaton,G.R. (2003) Eﬃcient use
of a ‘dead-end’ GA 50 splice site in the human ﬁbroblast growth
factor receptor genes. EMBO J., 22, 1620–1631.
81. Freund,M., Hicks,M.J., Konermann,C., Otte,M., Hertel,K.J. and
Schaal,H. (2005) Extended base pair complementarity between U1
snRNA and the 50 splice site does not inhibit splicing in higher
eukaryotes, but rather increases 50 splice site recognition.
Nucleic Acids Res., 33, 5112–5119.
82. Alvarez,C.J. and Wise,J.A. (2001) Activation of a cryptic 50 splice
site by U1 snRNA. RNA, 7, 342–350.
83. Newman,A. and Norman,C. (1991) Mutations in yeast U5 snRNA
alter the speciﬁcity of 50 splice-site cleavage. Cell, 65, 115–123.
84. Cortes,J.J., Sontheimer,E.J., Seiwert,S.D. and Steitz,J.A. (1993)
Mutations in the conserved loop of human U5 snRNA generate
the use of novel cryptic 50 splice sites in vivo. EMBO J., 12,
5191–5200.
85. Lesser,C.F. and Guthrie,C. (1993) Mutations in U6 snRNA that
alter splice site speciﬁcity: implications for the active site. Science,
262, 1982–1988.
86. Eperon,I.C., Ireland,D.C., Smith,R.A., Mayeda,A. and
Krainer,A.R. (1993) Pathways for selection of 50 splice sites by U1
snRNPs and SF2/ASF. EMBO J., 12, 3607–3617.
87. Maroney,P.A., Romfo,C.M. and Nilsen,T.W. (2000) Functional
recognition of 50 splice site by U4/U6.U5 tri-snRNP deﬁnes a novel
ATP-dependent step in early spliceosome assembly. Mol. Cell, 6,
317–328.
88. Konarska,M.M., Vilardell,J. and Query,C.C. (2006) Repositioning
of the reaction intermediate within the catalytic centre of the
spliceosome. Mol. Cell, 21, 543–553.
89. Valadkhan,S. and Manley,J.L. (2000) A tertiary interaction
detected in a human U2-U6 snRNA complex assembled
4262 Nucleic Acids Research, 2007, Vol. 35, No. 13in vitro resembles a genetically proven interaction in yeast. RNA, 6,
206–219.
90. Collins,C.A. and Guthrie,C. (1999) Allele-speciﬁc genetic interac-
tions between Prp8 and RNA active site residues suggest a function
for Prp8 at the catalytic core of the spliceosome. Genes Dev., 13,
1970–1982.
91. Vidal,V., Verdone,L., Mayes,A.E. and Beggs,J.D. (1999)
Characterization of U6 snRNA-protein interactions. RNA, 5,
1470–1481.
92. Crispino,J.D., Blencowe,B.J. and Sharp,P.A. (1994)
Complementation by SR proteins of pre-mRNA splicing reactions
depleted of U1 snRNP. Science, 265, 1866–1869.
93. Tarn,W.Y. and Steitz,J.A. (1994) SR proteins can compensate
for the loss of U1 snRNP functions in vitro. Genes Dev., 8,
2704–2717.
94. Krawczak,M. and Cooper,D.N. (1996) Single base-pair substitu-
tions in pathology and evolution: two sides to the same coin.
Hum. Mutat., 8, 23–31.
Nucleic Acids Research, 2007, Vol. 35, No. 13 4263